



PATENT
Attorney Docket 036870-5073-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Holroyd <i>et al.</i>)	
)	
Application No. 10/772,437)	Art Unit: 1646
)	
Filed: February 6, 2004)	Examiner: Prema Maria Mertz
)	
For: Methods for treating ICACC protein)	
associated diseases (Amended))	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Pursuant to 37 C.F.R. 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 forms. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

Copies of the listed documents are attached. The first document (aa) was received along with the Notice of Allowance in related U.S. Application 10/270,595 (now U.S. Patent 6,716,603). The second document (ab) was cited in a Partial European Search Report in related application EP 9991092.


Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **August 2, 2006**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801



INFORMATION DISCLOSURE CITATION		Attorney Docket 036870-5073-02	Application No. 10/772,737
(Use several sheets if necessary)		Applicants: Kenneth J. Holroyd <i>et al.</i> Page 1 of 1	
PTO Form 1449		Filing Date: February 6, 2004	Group Art Unit: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
	aa	Agnel <i>et al.</i> Identification of three novel members of the calcium-dependent chloride channel (CaCC) family predominantly expressed in the digestive tract and trachea. FEDS Letters 455: 295-301 (1999).	
	ab	Gruber <i>et al.</i> Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca ²⁺ -activated Cl ⁻ channel proteins, Genomics 54(2):200-14 (1998).	
Examiner		Date Considered	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			